Tag Archives: NASDAQ:REPH

Analysts Offer Insights on Healthcare Companies: Recro Pharma (NASDAQ: REPH) and Strongbridge Biopharma Plc (NASDAQ: SBBP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Recro Pharma (NASDAQ: REPH) and Strongbridge Biopharma Plc (NASDAQ: SBBP) with bullish sentiments. Recro Pharma (NASDAQ: REPH) Oppenheimer analyst Derek Archila maintained

Recro Pharma Gets a Buy Rating from Oppenheimer

In a report released today, Derek Archila from Oppenheimer maintained a Buy rating on Recro Pharma (NASDAQ: REPH). The company’s shares closed yesterday at $11.07. According to TipRanks.com, Archila is a 3-star analyst with an average return of 5.3% and

A Director at Recro Pharma is Exercising Options

Today, a Director at Recro Pharma, Michael Berelowitz, exercised options of Recro Pharma for $78.3K. This is Berelowitz’s first transaction since reporting a Sell transaction on ORMP back in December 2015 Based on Recro Pharma’s latest earnings report for the

Oppenheimer Sticks to Their Buy Rating for Recro Pharma

In a report released today, Derek Archila from Oppenheimer maintained a Buy rating on Recro Pharma (NASDAQ: REPH), with a price target of $19. The company’s shares opened today at $9.01. Archila wrote: “This morning, we attended REPH’s analyst day,

Roth Capital Sticks to Its Buy Rating for Recro Pharma

In a report issued on November 9, Scott Henry from Roth Capital reiterated a Buy rating on Recro Pharma (NASDAQ: REPH), with a price target of $18. The company’s shares closed yesterday at $8.75. According to TipRanks.com, Henry is a

Piper Jaffray Reiterates Their Buy Rating on Recro Pharma

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Recro Pharma (NASDAQ: REPH) on October 24 and set a price target of $11. The company’s shares closed yesterday at $8.63. According to TipRanks.com, Amsellem is a 1-star analyst with